NEW
YORK, Nov. 6, 2023 /PRNewswire/ -- Delcath
Systems, Inc. (Nasdaq: DCTH), an interventional oncology
company focused on the treatment of primary and metastatic cancers
of the liver, announced today it will host a conference call on
November 13, 2023, at 4:30 PM Eastern Time to discuss results for its
third quarter ended September 30,
2023.
Conference Call
Information
To participate in this event, dial approximately 5 to 10 minutes
before the beginning of the call.
Event Date: Monday, November 13,
2023
Time: 4:30 PM Eastern Time
Participant Numbers: Toll Free: 1-833-630-1960
International: 1-412-317-1841
Webcast: https://app.webinar.net/w2e6oOR1rPL
CONFERENCE
REPLAY
|
US Toll
Free:
|
1-877-344-7529
|
International
Toll:
|
1-412-317-0088
|
Replay Access
Code:
|
6614259
|
End Date:
|
November 20,
2023
|
About Delcath Systems,
Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The Company's proprietary products, HEPZATO KIT (melphalan for
Injection/Hepatic Delivery System), approved for use in
the United States by FDA, and
CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic
perfusion (PHP), designated under the medical device regulation for
use in Europe and the United Kingdom, are designed to administer
high-dose chemotherapy to the liver while controlling systemic
exposure and associated side effects during a PHP procedure. For
more information regarding HEPZATO KIT and its use, including
Important Safety Information and Boxed Warning, please visit
HEPZATOKIT.com. For more information regarding CHEMOSAT and its
use, please visit Chemosat.com.
Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-host-third-quarter-2023-results-call-301979153.html
SOURCE Delcath Systems, Inc.